Congress Update Service, Issue for August 2011 2011 European Multidisciplinary Cancer Congress: Spotlight on
22 days and counting until the largest European Multidisciplinary Cancer
Congress takes place in Stockholm! 262 Scientific Committee members have
jointly compiled an outstanding 33-Track programme containing the latest
developments in cancer research, treatment and care. This meeting provides a
unique platform for all professionals with a common interest in oncology to
discuss, debate and deliberate new data.
285 sessions host over 2,000 presentations from 707 eminent experts containing
their latest data, knowledge and experience. The programme has attracted a
record number of late-breaking abstracts, presenting practice-changing data in
four presidential sessions and 25 proffered paper sessions. A must attend for all!
If you have yet to register, avail of our 20% discount on the late rate registration
fee to members of one of ECCO’s member societies only (875 instead of 1,095
EUR. This offer is not applicable to nursing, student and patient advocate rates). Hot New Data - Hot New Data - Pick of the Programme ECCO16 - ESMO36 - Secretariat
file:///C|/Users/nicola.FECS/Desktop/Issue7_August2011_rev3.htm[07/10/2011 15:05:42]
Hot New Data - not to be missed!
Presidential sessions: Late-Breaking and Best Abstracts
Saturday 24 September 2011, 13:45 - 15:35 Presidential Session I: Best and Late-Breaking Abstracts
Best Abstract: A Pivotal Multicenter Trial Evaluating Efficacy and Safety of
the Hedgehog Pathway Inhibitor (HPI) Vismodegib in Patients with Advanced
L. Dirix, M.R. Migden, A.E. Oro, A. Hauschild, K. Lewis, A.B.Mueller, R. Yauch, J.C. Reddy, A. Sekulic:
Late-Breaking Abstract: Overall Survival Benefit of Radium-223 Chloride
(Alpharadin™) in the Treatment of Patients with Symptomatic Bone
Metastases in Castration-resistant Prostate Cancer (CRPC): a Phase III
C. Parker, D. Heinrich, J.M. O'Sullivan, S. Fosså, A. Chodacki, T.Demkow, A. Cross7, B. Bolstad, J. Garcia-Vargas, O. Sartor:
Late-Breaking Abstract: Very Accelerated Radiotherapy (RT) Versus
Concomitant Chemo-Radiotherapy (Ct-Rt) In Locally Advanced Head and
Neck Cancer: Long Term Results from 2 Phases III GORTEC Randomised
J. Bourhis, C. Sire, P. Graff, V. Grégoire, P. Maingon, M. Lapeyre,J.C.G. Tortochaux, B. Gery, L. Martin, M. Alfonsi, P. Deprez, T.Pignon, E. Bardet, M. Rives, A. Pinna, M. Ducoutieux, A. Aupérin:
Late-Breaking Abstract: Everolimus in Subependymal Giant Cell
Astrocytomas (SEGA) Associated with Tuberous Sclerosis Complex (TSC):
Results of EXIST-1, a Double-Blind Placebo-controlled Phase 3 Trial
M. Bebin, D.N. Franz, T. Sahmoud, E. Belousova, S. Sparagana, M. 4LBAFrost, J. Ford, G. Shah, H. Cauwel, S. Jozwiak:Sunday 25 September, 12:20 - 14:40 Presidential Session II: Best and Late-Breaking Abstracts
Best Abstract: Synchronous Chemo-radiation Can Reduce Local Recurrence
in Early Stage Breast Cancer: Results of the SECRAB Trial (ISRCTN:
file:///C|/Users/nicola.FECS/Desktop/Issue7_August2011_rev3.htm[07/10/2011 15:05:42]
84214355) Presented on Behalf of the SECRAB Steering Committee
I. Fernando, S.J. Bowden, C.L. Brookes, R. Grieve, D. Spooner,R.K. Agrawal, A.M. Brunt, M. Churn, D.W. Rea, P. Canney:
Late-Breaking Abstract: Results from VELOUR, a Phase 3 Study of
Aflibercept (A) Versus Placebo (pbo) in Combination with FOLFIRI for the
Treatment of Patients (pt) with Previously Treated Metastatic Colorectal
J. Tabernero, E. Van Cutsem, R. Lakomy, J. Prausova, P. Ruff, G.Van Hazel, V. Moiseyenko, D. Ferry, J. McKendrick, K. Soussan-
Late-Breaking Abstract: Efficacy in Patient Subgroups in OCEANS, a
Randomized, Double-blinded, Placebo-controlled, Phase 3 Trial of
Chemotherapy ± Bevacizumab in Patients with Platinum-sensitive Recurrent
Epithelial Ovarian (OC), Primary Peritoneal (PPC), or Fallopian Tube Cancer
C. Aghajanian, S.V. Blank, B. Goff, P.L. Judson, S. Makhija, S.K.Sharma, L.R. Nycum, J. Yi, A. Husain:
Late-Breaking Abstract: A Multicentre Randomised Trial of Ibandronate
Compared to Single Dose Radiotherapy for Localised Metastatic Bone Pain
P. Hoskin, S. Sundar, K. Reczko, S. Forsyth, N. Mithal, B. Sizer, L.Monday 26 September, 12:15 - 14:25 Presidential Session III: Best and Late-Breaking Abstracts
Late-Breaking Abstract: Delivering Affordable Cancer Care in High-income
R. Sullivan, J. Peppercorn, K. Sikora, J. Zalcberg, N. Meropol, E.Amir, D. Khayat, P. Boyle, I. Tannock, T. Fojo:
Best Abstract: VANTAGE 014: Vorinostat in Patients With Advanced
Malignant Pleural Mesothelioma (MPM) Previously Treated With Pemetrexed
and Either Cisplatin or Carboplatin Therapy: a Phase III, Randomized,
L.M. Krug, H.L. Kindler, H. Calvert, C. Manegold, A.S. Tsao, D.Fennell G.M. Lubiniecki, X. Sun, M.M. Smith, P. Baas:
Late-Breaking Abstract: Everolimus in Combination with Exemestane for
Postmenopausal Women with Advanced Breast Cancer Who Are Refractory
to Letrozole or Anastrozole: Results Of the BOLERO-2 Phase III Trial
J. Baselga, M. Campone, T. Sahmoud, M. Piccart, H. Burris, H.Rugo, S. Noguchi, M. Gnant, P. Mukhopadhyay, G. Hortobagyi:
Late-Breaking Abstract: The EORTC 10041/BIG 03-04 MINDACT (Microarray
in Node Negative and 1 to 3 Positive Lymph Node Disease May Avoid
ChemoTherapy) Trial: Patients' Baseline Characteristics and Logistics
M. Piccart, J. Bogaerts, F. Cardoso, G. Werutsky, S. Delaloge, L.
file:///C|/Users/nicola.FECS/Desktop/Issue7_August2011_rev3.htm[07/10/2011 15:05:42]
Van 't Veer6, I. Rubio7, C. Moulin8, K. Engelen9, G. Viale10, A.M.Thompson, R. Passalacqua, U. Nitz, P. Vuylsteke, J.Y. Pierga, E.
Late-Breaking Abstract: Laparoscopic Surgery Versus Open Surgery for
Rectal Cancer: Short-term Outcomes of a Randomised Trial
H.J. Bonjer, E. Haglind, M.A. Cuesta, A. Fürst, A. Lacy, M.H.G.M.van der Pas, W.C.J. Hop, The COLOR II Study Group:AHot New Data - Part Two
Late Breaking Abstracts in Proffered Paper sessions
Saturday 24 September 2011 Proffered Papers Session: Gastrointestinal Malignancies - Colorectal Cancer, 11:15 - 13:50
Late-Breaking Abstract:A Phase 2b, Double-Blind, Randomized Study
Evaluating the Efficacy and Safety of Sorafenib (SOR) Compared With
Placebo (PBO) When Administered in Combination With Chemotherapy
(Modified FOLFOX6) for First-line Treatment (tx) of Patients (Pts) With
Metastatic Colorectal Cancer (mCRC), the RESPECT Trial
J. Tabernero, R. Garcia-Carbonero, C.H. Köhne, P.J. O'Dwyer, A.Sobrero, E. Van Cutsem, O. Gladkov, I. Davidenko, R. Salazar, J.Proffered Papers Session: Lung Cancer-Metastatic, 11:15
Late-Breaking Abstract: A Phase II Study of Sorafenib in Patients with
Locally Advanced And/or Metastatic (stage IIIB or IV) Non-small Cell Lung
A.M. Dingemans, W.W. Mellema, H.J.M. Groen, A. van Wijk, S.Burgers, P.W.A. Kunst, F.B. Thunnissen, D.A.M. Heideman, E.F.
Late-Breaking Abstract: AVAPERL (MO22089): Final Efficacy Outcomes for
Patients (pts) With Advanced Non-squamous Non-small Cell Lung Cancer
(nsNSCLC) Randomised to Continuation Maintenance (mtc) with
Bevacizumab (bev) or Bev+Pemetrexed (pem) After First-line (1L) Bev-
F. Barlesi, J. de Castro, V. Dvornichenko, J.H. Kim, A. Pazzola, A.Rittmeyer, A. Vikström, L. Mitchell, E.K. Wong, V. Gorbunova:Proffered Papers Session: Head and Neck Cancer, 11:15 -
Late-Breaking Abstract: Safety and Efficacy of Panitumumab (pmab) in HPV
Positive (+) and HPV Negative (-) Recurrent/metastatic (R/M) Squamous Cell
Carcinoma of the Head and Neck (SCCHN): Analysis of the Phase 3
file:///C|/Users/nicola.FECS/Desktop/Issue7_August2011_rev3.htm[07/10/2011 15:05:42]
J. Vermorken, J. Stöhlmacher, K. Oliner, C. Villanueva, P. Foa, E.Winquist, L. Licitra, K. Skladowski, Z. Pan, B.A. Bach:Proffered Papers Session: Melanoma and Skin Cancer, 11:15 - 13:15
Late-Breaking Abstract: Vemurafenib Improves Overall Survival Compared to
Dacarbazine in Advanced BRAFV600E-mutated Melanoma: Updated
Survival Results From a Phase III Randomised, Open-label, Multicentre Trial
G. McArthur, A. Hauschild, C. Robert, J.B. Haanen, P. Ascierto,R.J. Lee, K. Nolop, B. Nelson, K.T. Flaherty, P.B. Chapman:Sunday 25 September 2011 Proffered Papers Session: Breast Cancer - Advanced Disease, 09:00 - 11:35
Late-Breaking Abstract: Reversal of Tamoxifen Resistance (Hormone
Resistance) by Addition of Sirolimus (mTOR Inhibitor) in Metastatic Breast
G.S. Bhattacharyya, J. Biswas, J.K. Singh, M. Singh, K.Govindbabu, A.A. Ranade, H. Malhotra, P.M. Parikh, T. Shahid, S.
Late-Breaking Abstract:A Double-blind, Randomized Phase IIb Study
Evaluating the Efficacy and Safety of Sorafenib (SOR) Compared to Placebo
(PL) When Administered in Combination with Docetaxel And/or Letrozole in
Patients with Metastatic Breast Cancer (MBC): FM-B07-01 Trial
G. Mariani, O. Burdaeva, L. Roman, E. Staroslawska, D. Udovitsa,P. Driol, G. Goisis, C. Zamagni, V. Semiglazov, L. Gianni:Proffered Papers Session: Personalised Medicine, 09:00 -
Late-Breaking Abstract: Evaluation of Individual Codon 12 and 13 Mutant
(MT) KRAS Alleles as Prognostic and Predictive Biomarkers of Response to
Panitumumab (pmab) in Patients with Metastatic Colorectal Cancer (mCRC)
M. Peeters, J.Y. Douillard, E. Van Cutsem, S. Siena, K. Zhang, R.Proffered Papers Session: Lung Cancer-Localised/Local Regional, 09:00 - 10:30
Late-Breaking Abstract: Results of a Pilot External Quality Assurance
Scheme for Somatic EGFR Mutation Testing in Non-Small Cell Lung Cancer
N. Normanno, S. Patton, S. Murray, F. Blackhall, K.M. Kerr, M.Dietel, M. Filipits, M. Taron, R. Stahel, E. Thunnissen:Proffered Papers Session: Genitourinary Malignancies - Prostate Cancer, 09:00 - 11:00
Late-Breaking Abstract: Celecoxib Plus Hormone Therapy Vs Hormone
Therapy Alone for Hormone-sensitive Prostate Cancer: First Results From
the STAMPEDE Randomised Controlled Trial (MRC PR08), On Behalf of the
file:///C|/Users/nicola.FECS/Desktop/Issue7_August2011_rev3.htm[07/10/2011 15:05:42]
N.D. James, M.R. Sydes, M.D. Mason, N.W. Clarke, D.P.Dearnaley, J. Dwyer, G. Jovic, J.M. Russell, G. Thalmann, M.K.B.
Late-Breaking Abstract: Escalated-dose Conformal Radiotherapy for
Localised Prostate Cancer: Long-term Overall Survival Results From the
MRC RT01 Randomised Controlled Trial, On Behalf of the RT01
D.P. Dearnaley, G. Jovic, I. Syndikus, J.D. Graham, E.G. Aird, V.Proffered Papers Session: Central Nervous System, 09:00
Late-Breaking Abstract: Clinical, Molecular, and Molecular-Clinical Profile
(MCP) Exploratory Subset Analysis of RTOG 0525: a Phase III Trial
Comparing Standard (std) Adjuvant Temozolomide (TMZ) with a Dose-dense
M. Mehta, M. Wang, K. Aldape, E. Sulman, R. Stupp, K. Jaeckle, D. 18LBABlumenthal, S. Erridge, W. Curran, M. Gilbert):Monday 26 September 2011 Proffered Papers Session: Gynaecological Cancer, 09:00 -
Late-Breaking Abstract: Quality of Life Outcomes of a Randomized, Placebo-
Controlled Trial of Bevacizumab in the Front-Line Treatment of Ovarian
Cancer: a Gynecologic Oncology Group Study
B.J. Monk, H. Huang, R.A. Burger, R.L. Mannel, H.D. Homesley, J.Fowler, B.E. Greer, M. Boente, S.X. Liang, L. Wenzel:
Late-Breaking Abstract: Quality of Life in the ICON7 GCIG Phase III
D. Stark, M. Nankivell, F. Hilpert, L. Elit, J. Brown, A. Lanceley, G.Valikova, A. Oza, A.M. Swart, T. Perren:
Late-Breaking Abstract: Mutation and Protein Expression Biomarkers
Correlate with Response to AKT Inhibition in a Phase I Trial of the Oral Pan
AKT Inhibitor GSK2141795 (GSK795) in Patients (pts) with Platinum
H. Gungor, E. Stronach, E. Curry, A. Saleem, R. Agarwal, S.Blagden, S. Babar, G. Mills, S.R. Morris, H. Gabra:Oncology Nursing Proffered Papers Session: Nursing - Supportive Care, 09:00 - 11:15
Late-Breaking Abstract: Unrecognised and Underprepared: an Exploratory
Mixed Method Study of Informal Carers’ Experiences of Supporting
E. Ream, V. Pedersen, C. Oakley, A. Richardson, C. Taylor, R.
file:///C|/Users/nicola.FECS/Desktop/Issue7_August2011_rev3.htm[07/10/2011 15:05:42]
Proffered Papers Session: Basic Science/Translational Research, 14:45 - 17:10 Late-Breaking Abstract: Drugging the Undruggable: Small-molecule Inhibition G. Fang, T. Maurer, L. Garrenton, N. Skelton, B. Fauber, S. Malek, 15LBAA. Giannetti, P. Jackson, J. Rudolph, W. Wang:Tuesday 27 September 2011 Proffered Papers Session: Sarcoma, 09:00 - 11:30
Late-Breaking Abstract: A Randomized Clinical Trial of Adjuvant
Chemotherapy with Doxorubicin, Ifosfamide, and Cisplatin in Localized
Uterine Sarcomas. Results on 81 Randomized Patients
P. Pautier, A. Floquet, L. Gladieff, D. Berton-Rigaud, S. Piperno-Neumann, F. Selle, I. Ray-Coquard, C. Guillemet, B. Weber, A.
Late-Breaking Abstract: Denosumab Treatment for Giant Cell Tumour of
Bone (GCTB) in Adolescent Patients: Interim Results From a Phase 2 Study
J. Engellau, S. Chawla, R. Grimer, A. Powell, S. Schuetze, K.Skubitz, A. Staddon, C. Atchison, Y. Zhao, I. Jacobs:
Late-Breaking Abstract: Response to Imatinib Rechallenge of GIST That
Recurs Following Completion of Adjuvant Imatinib Treatment - the First
Analysis in the SSGXVIII/AIO Trial Patient Population
P. Reichardt, J.T. Hartmann, K. Sundby Hall, M. Eriksson, J.Schütte, G. Ramadori, P. Hohenberger, J. Duyster, M. Leinonen, H. 31LBAJoensuu:Pick of the Programme Proffered Paper Session on Personalised Medicine, Sunday 25 September, 09:00-10:50
Biomarkers are becoming more important in determining effectiveness of
treatment response. This session highlights the latest data in detecting novel
mutations in NSCLC, colorectal cancer and melanoma. Featuring studies on
evaluating plasma VEGFA as potential biomarker following treatment of
Bevacizumab, it also includes a study on using dynamic contrast-enhanced
ultrasound (DCE-US) as an effective tool to evaluate antiangiogenic
Special Session on MIRACLE Workshop: Novel Technologies for the Isolation and Analysis of Circulating Tumour Cells, 14:45-16:45
Circulating tumour cells (CTC) and disseminating tumour cells (DTC) are cells
detached from the primary tumour, acting as seeds for tumour growth on other
sites and are very important predictive and prognostic markers for the
file:///C|/Users/nicola.FECS/Desktop/Issue7_August2011_rev3.htm[07/10/2011 15:05:42]
treatment of advanced cancer. However, with very low levels of CTCs in the
blood, they are difficult to detect and isolate.
One of two special sessions, the MIRACLE workshop will discuss
development of novel technologies to detect CTCs and issues and hurdles to
be overcome to produce highly sophisticated devices to detect minute
quantities of CTCs and DTCs in the blood and bone marrow. Leading experts
in bioengineering and nanotechnology, Leo Terstappen, Philip Gascoyne,
Chiwee Teck Lee and Lisbet Lagae will discuss and address these issues.
MIRACLE is a collaborative project between 14 partners from universities,
research institutions and companies from all over Europe. The term MIRACLE
is an acronym of the projects title ‘Magnetic Isolation and moleculaR Analysis of single CircuLating and disseminated tumour cElls on chip’. The project is funded by the European Commission within the 7th Framework Special Session on Circulating Tumour Cells, Monday 26 September, 13.15-14.15
This session will present the use of CTCs in the clinic and existing
technologies for detecting CTCs and their markers.
Klaus Plantel will discuss the reasons for monitoring CTCs during and after
systemic adjuvant therapy. Stefan Sleijfer will present the importance of CTC
enumeration and characterisation. Caroline Dive will discuss the technological
This session also features a highly interactive discussion on how the detection
Special Session on Stem Cells, Sunday 25 September, 13.15-14.15
Stem cells are core cells that can divide and differentiate into different types
of specialised cells, and can self renew in more cells. Stem cell research has
been performed across multiple diseases, most notably Parkinson’s disease.
This session will cover cancer stem cells in different tumour types. Rune
Toftgard will discuss stem cells in skin cancer. Per Giuseppe Pelicci will talk
about haematopoietic stem cells and Simone Niclou will consider cancer stem
Each presentation will highlight the importance of cancer stems cells in the
survival of the tumour and the implications to future cancer treatments. Official Media Partners: DISCLAIMER
You have been sent this email because you have subscribed online at
file:///C|/Users/nicola.FECS/Desktop/Issue7_August2011_rev3.htm[07/10/2011 15:05:42]
to receive this Congress Update Service, or have attended or expressed an
interest in an ECCO event in the past. If you do not wish to continue to receive this
special Update Service, please forward this message to the
file:///C|/Users/nicola.FECS/Desktop/Issue7_August2011_rev3.htm[07/10/2011 15:05:42]
In return for free usage of this material, we ask that you: tell us where it’s going to be published include the byline (including a link to our website) How To Create Speculative Ads For Your Portfolio If you want to get work in an advertising agency, your portfolio is vital! Here’s a series of great briefs to get stuck into. Follow the brief, come up with at least 25 great ideas for
Agitation? Delirium? Both? and What to Do About It Kathryn T. Von Rueden RN, MS, ACNS-BC, FCCM Clinical Nurse Specialist, R Adams Cowley Shock Trauma Center, Assistant Professor University of Maryland, School of Nursing Delirium: “a part of the scenery ?” Ely, W: Semin Respir Crit Care Med. 2001;22(2) Delirium : DSM-IV Diagnostic Criteria reduced clarity of awareness of the
Congress Update Service, Issue for August 2011
treatment of advanced cancer. However, with very low levels of CTCs in the
blood, they are difficult to detect and isolate.